Pasar al contenido principal

MECANISMOS MOLECULARES DE LOS SINTOMAS NO MOTORES EN LA ENFERMEDAD DE PARKINSON: PAPEL DE LA ACUMULACION DE LA A-SINUCLEINA, GBA1 Y EL PETABOLISMO LIPIDICO

PID2019-111693RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia

  • Tizabi, Yousef
  • Getachew, Bruk
  • Copeland, Robert L.
  • Moratalla, Rosario
  • Patricio, Felipe
  • Limón, Ilhuicamina Daniel
  • Del-Bel, Elaine
  • Aschner, Michael
Dyskinesia or abnormal involuntary movement is an unfortunate consequence of long-term therapy with L-DOPA, a gold standard for the treatment of Parkinson’s disease (PD). L-DOPA-induced dyskinesia (LID) is affected by age of onset, duration and severity of PD, L-DOPA dose, as well as gender. The main treatment modality is reduction of L-DOPA dose. Although administration of apomorphine, amantadine, and clozapine may be helpful, more effective pharmacotherapies are urgently needed. Recent advances in our understanding of the pathophysiology of LID have led to suggestions of novel interventions. In this chapter, three classes of drugs, nicotinic receptor agonists, glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonists, and cannabinoid receptor agonists, where their effectiveness in preclinical studies has been established, will be discussed in detail., Supported in part by the Howard University College of Medicine Bridge Funds and Pilot Study Awards Program (BFPSAP) 2020–2021 (YT, RLC); Spanish Ministry of Science and Innovation (PID2019-111693RBI00) and European Union’s Horizon 2020 research and innovation program, AND-PD (grant agreement no. 848002) (RM); VIEP-BUAP 2020-2021(IDL); São Paulo State Foundation for the Support of Research (FAPESP, Brazil; Grants 2014/25029-4 and 2017/24304-0), CAPES-COFECUB Grant #848/15) (EDB); and NIH/NIEHS R01ES10563 (MA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Two factor model of L-DOPA-induced dyskinesia: bridging early clinical findings with modern mechanistic understanding.

  • Moratalla, Rosario
  • Murer, Mario Gustavo
l-DOPA-induced dyskinesia (LID) remains a major complication of dopaminergic therapy in Parkinson's disease (PD), and serves as a model for studying maladaptive plasticity induced by dopaminergic overstimulation, with relevance to other disorders such as addiction. Chronic striatal dopamine depletion is crucial for LID development, inducing pruning of corticostriatal synapses—particularly on direct pathway medium spiny neurons (dMSNs)—and thereby distorting striatal input-output mapping. Superimposed on this structural remodeling, repeated pulsatile l-DOPA treatment leads to sensitization of dMSNs, resulting in heightened dopaminergic and glutamatergic responsiveness, impaired synaptic depotentiation, and recruitment of hyperactive dMSN ensembles during dyskinesia. Concurrently, indirect pathway MSNs (iMSNs) undergo dynamic adaptations in excitability and ensemble activity that modulate the threshold for LID expression, possibly through disinhibition of dMSN output. Recent optogenetic studies in parkinsonian mice support a model in which dopaminergic denervation alone sculpts a dMSN network capable of producing dyskinesia upon activation even in animals never previously exposed to dopamine receptor stimulation. Intermittent l-DOPA administration further sensitizes this network without qualitatively altering the abnormal movements. In parallel, iMSN optogenetic inhibition produces therapeutic effects, while their stimulation reduces established LID, indicating a modulatory role for the indirect pathway. These findings support a two-factor model of LID in which (1) striatal denervation distorts corticostriatal input-output relationships, and (2) plastic changes in dMSNs and iMSNs lower the threshold for dyskinetic output in response to dopaminergic stimulation. In early PD, the therapeutic effects of l-DOPA are likely mediated by balanced D2 receptor stimulation on iMSNs and D1 receptor stimulation in dMSNs, providing symptom relief without provoking dyskinesia. However, disease progression and chronic l-DOPA therapy appear to partially reverse denervation-induced changes in iMSNs, including normalization of D2 receptor expression, restoration of intrinsic excitability, and partial recovery of dendritic spine density, which could contribute to a gradual desensitization of D2/iMSN influence over time, leading to an increased reliance on dMSN-mediated mechanisms for both therapeutic and dyskinetic effects. This hypothesis offers a mechanistic explanation for the temporal dissociation between the therapeutic and dyskinetic effects of l-DOPA in early disease, and their progressive narrowing of the therapeutic window as disease and treatment duration advance., We thank Cecilia Tubert (IFIBIO Houssay, Buenos Aires, Argentina) for her assistance with the figures. This work was supported by grants from the Universidad de Buenos Aires, PIDAE 2024-7, and FONCYT, PICT 2020 325 (MGM), and PID 2022-148131OB-100, funded by MICIN/AEI/10.13039/501100011033, and by European Union’s Horizon 2020 research and innovation program, AND-PD (Grant Agreement No. 84800), MJFF-022990, CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III (RM).